BATF2 and glioblastoma: In addition, survival outcomes differed by GBM tumor subtype, with minimal effects observed in mesenchymal and neural forms, indicating that additional genetic variations present across subtypes of GBM impact the efficacy of BATF2 as a tumor suppressor.